All In Biotech

Free tool

FAERS Monitor: Imaavy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761430 or its brand name (Imaavy, Nipocalimab-Aahu). Reports on generic versions are filed under their own applications.

Reports

318

Serious

119

37% of reports

Hospitalization

67

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective30
  • myasthenia gravis25
  • headache20
  • oedema peripheral20
  • fatigue18
  • dyspnoea16
  • influenza14
  • off label use14
  • product dose omission issue13
  • infusion related reaction11
  • rash11
  • therapeutic response decreased11
  • herpes zoster10
  • pneumonia10
  • asthenia9

Reports by year received

View as table
YearReports
202588
2026230

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,841 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myasthenia gravisSignal25205.4140.94,869
therapeutic response decreasedSignal1112.06.7100
herpes zosterSignal1011.56.386
infusion related reactionSignal1111.06.190
oedema peripheralSignal2010.97.1170
influenzaSignal148.35.083
product dose omission issueSignal132.91.715
headacheSignal202.11.411
pneumoniaSignal102.01.14
dyspnoea161.91.26
rash111.70.92
asthenia91.60.81
fatigue181.51.03
drug ineffective301.51.15
off label use141.10.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.